<DOC>
	<DOCNO>NCT00018018</DOCNO>
	<brief_summary>This study evaluate new method deliver gene transfer therapy patient severe combine immunodeficiency disease ( SCID ) due defective adenosine deaminase ( ADA ) gene . This gene cod adenosine deaminase enzyme , essential proper growth function infection-fighting white blood cell call T B lymphocytes . Patients lack enzyme vulnerable frequent severe infection . Some patient disease receive enzyme replacement therapy weekly injection drug PEG-ADA ( ADAGEN ) . This drug may increase number immune cell reduce infection , cure . Gene transfer therapy , normal ADA gene insert patient cell , attempt correct underlie cause disease . This therapy try small number patient vary degree success . In study , gene inserted patient stem cell ( cell produce bone marrow mature different blood component white cell , red cell platelet ) . Patients ADA deficiency SCID take PEG-ADA candidate HLA-identical sibling donor bone marrow transplantation may eligible study . Participants admit NIH Clinical Center 2 3 day . Stem cell collect either cord blood ( newborn patient ) bone marrow . The bone marrow procedure do light sedation general anesthesia . It involve draw small amount marrow needle insert hip bone . The stem cell marrow grown laboratory normal human ADA gene transfer special type disable mouse virus . A day later , patient receive ADA-corrected cell infusion vein last 10 minute 2 hour . Patients evaluate periodically immune function blood test , skin test , reaction tetanus , diphtheria , H. influenza B S. pneumoniae vaccination . The survival ADA-corrected cell monitor blood test . The number amount blood test depend patient age , weight health , expect blood drawn twice month . Patients also undergo bone marrow biopsy aspirate ( describe ) twice year . Patients follow year indefinitely evaluate long-term effect therapy .</brief_summary>
	<brief_title>Gene Transfer Therapy Severe Combined Immunodeficieny Disease ( SCID ) Due Adenosine Deaminase ( ADA ) Deficiency</brief_title>
	<detailed_description>This clinical gene transfer study aim verify safety efficacy use retroviral vector introduce human adenosine deaminase ( ADA ) gene hematopoietic progenitor patient affect severe combine immunodeficiency due ADA deficiency . In addition , protocol examine effect ADA gene transfer immune system treat patient . Patients ADA deficiency ineligible match sibling allogeneic bone marrow transplantation eligible participate study . To increase engraftment selective advantage gene-corrected cell , busulfan use cytoreduction agent enzyme replacement ( PEG-ADA ) therapy discontinue . CD34+ hematopoietic progenitor isolate patient bone marrow cord blood , expose retroviral vector-mediated gene transfer reinfused patient peripheral vein . Clinical , immunological molecular follow-up study ass safety , toxicity , efficacy procedure .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients enrol study fulfill follow three criterion : A . Patients age great equal 1 month diagnosis ADAdeficiency base : 1 . Confirmed absence ( le 3 % normal level ) ADA enzymatic activity peripheral blood ( neonate ) umbilical cord erythrocytes and/or leukocyte , culture fetal cell derive either chorionic villus biopsy amniocentesis , prior institution enzyme replacement therapy . AND 2 . Evidence severe combine immunodeficiency base either : Family history first order relative ADA deficiency clinical laboratory evidence severe immunologic deficiency OR Evidence severe immunologic deficiency subject base lymphopenia ( absolute lymphocyte count le 200 ) severely decrease T lymphocyte blastogenic response phytohemagglutinin ( cpm le 5,000 ) prior institution immune restorative therapy OR 3 . Evidence genetic mutation affect ADA gene determine CLIA certify laboratory clinical evidence combine immunodeficiency base lymphopenia ( absolute lymphocyte count less 2SD agematched control value ) hypogammaglobulinemia ( le 2SD agematched control value ) lack specific antibody response vaccination . Evidence lifethreatening illness ( increased frequency and/or severity infection result hospitalization and/or administration intravenous antibiotic ) necessary patient eligible criterion . B . Patients ineligible allogeneic ( matched sibling ) bone marrow transplantation ( BMT ) base : 1 . Absence medically eligible HLAidentical sibling normal immune function may serve allogenic bone marrow donor OR 2 . Election parent adult patient forgo allogeneic BMT favor PEGADA enzyme therapy invite discuss alternative treatment option physician connect protocol . C. Written inform consent accord guideline NHGRI IRB , NIH Committee Clinical Investigations ( CCI ) Children 's Hospital Los Angeles ( CHLA ) . This study also open delayed/late onset ADAdeficient patient fulfill criterion A , B.1 , C receive PEGADA treatment invite discuss alternative treatment option physician connect protocol . EXCLUSION CRITERIA : Age : . Age less 1 month Hematologic : 1 . Anemia ( hemoglobin le 10.5 mg/dl , subject 2 year age less hemoglobin less 11.5 mg/dl subject older 2 year age presence normal iron study ) . 2 . Neutropenia i. absolute granulocyte count &lt; 500/mm ( 3 ) ii . absolute granulocyte count 500999/mm ( 3 ) ( age 112 month ) 5001,499/mm ( 3 ) age &gt; 1 year ) bone marrow study show myelodysplasia gross abnormality . c. Thrombocytopenia ( platelet count le 150,000 mm ( 3 ) age ) d. PT PTT great 2 time normal . e. Cytogenic abnormality peripheral blood . Infectious : . Evidence active opportunistic infection infection HIV1 , hepatitis B , CMV parvovirus B19 DNA PCR time assessment . Pulmonary : 1 . Resting O2 saturation pulse oximetry less 95 % . 2 . Chest Xray indicate active progressive pulmonary disease . Cardiac : 1 . Abnormal electrocardiogram ( EKG ) indicate cardiac pathology . 2 . Uncorrected congenital cardiac malformation . 3 . Active cardiac disease , include clinical evidence congestive heart failure , cyanosis , hypotension . Neurologic : 1 . Significant neurologic abnormality examination . 2 . Uncontrolled seizure disorder . Renal : 1 . Renal insufficiency : pediatric patient serum creatinine great equal 1.2 mg/dl , great equal 3+ proteinuria , adult value grade great equal NCI Common Toxicity Criteria ( CTC ) . 2 . Abnormal serum sodium , potassium , calcium , magnesium , phosphate grade III IV DAIDS Toxicity Scale NCI CTC . Hepatic/Gl : 1 . Serum transaminases great 5 time normal . 2 . Serum bilirubin great 3.0 mg/dl . 3 . Serum glucose great 250 mg/dl . 4 . Intractable severe diarrhea . Oncologic : . Evidence active malignant disease dermatofibrosarcoma protuberans ( DFSP ) General : 1 . Expected survival le 6 month . 2 . Major congenital anomaly . 3 . Subject pregnant . 4 . Medically eligible HLAidentical sibling available . 5 . Known hypersensitivity busulfan . 6 . Other condition opinion P.I . coinvestigators , contraindicate infusion transduce cell ability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 17, 2014</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>ADA-SCID</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Retroviruses</keyword>
	<keyword>Immune Deficiency Disease</keyword>
	<keyword>Adenosine Deaminase Deficiency</keyword>
	<keyword>ADA-Deficiency</keyword>
	<keyword>Retroviral Vectors</keyword>
	<keyword>Hematopoietic Progenitors</keyword>
	<keyword>Severe Combined Immunodeficiency</keyword>
	<keyword>SCID</keyword>
	<keyword>Immune Deficiency</keyword>
</DOC>